99
Participants
Start Date
October 29, 2018
Primary Completion Date
March 2, 2022
Study Completion Date
March 30, 2022
Placebo Oral Tablet
twice daily administration
Alvelestat oral tablet - dose 1
twice daily administration
Alvelestat oral tablet - dose 2
twice daily administration
Gentofte Hospital, Hellerup
UZ Leuven, Leuven
Synddansk Universitet (SDU) - Odense University, Odense
Aarhus Universitetshospital, Aarhus
UZ Gent, Ghent
Lund University Hospital, Lund
PMG Research of Wilmington, Wilmington
University of Alabama, Birmingham (UAB), Birmingham
CTC Gothia Forum Sahlgrenska University Hospital, Gothenburg
UCLA Medical Center, Los Angeles
UC Davis Medical Centre, Sacramento
The University Lung Clinic, Edmonton
Centre for Heart Lung Innovation, St Pauls Hospital, Vancouver
Inspiration Research Ltd, Toronto
University of Saskatchewan Royal University Hospital, Saskatoon
Instytut Gruzilicy Chorob Pluc, Warsaw
Hospital Univ Clinico San Carlos, Madrid
Hospital Sierrallana, Torrelavega
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Cambridge University Hospitals Foundation NHS Trust, Cambridge
University Hospital Coventry and Warwickshire, Coventry
Royal Infirmary of Edinburgh, Edinburgh
Royal Devon and Exeter NHS Trust, Exeter
University Hospitals of Leicester NHS Trust, Leicester
Royal Brompton Hospital, London
Southampton General Hospital, Southampton
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
Mereo BioPharma
INDUSTRY